Growth hormone deficit: Influence of puberty on the response to treatment.

Autor:	Sánchez Malo MJ; Servicio de Pediatría, Hospital Reina Sofía, Tudela, Navarra, Spain. Electronic address: mjsanchezmalo@gmail.com., Hidalgo Sanz J; Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain., Hernández Tejedor C; Servicio de Pediatría, Hospital Universitario Miguel Servet, Zaragoza, Spain., García Ventura M; Centro de Salud Valdespartera, Zaragoza, Spain., Ferrer Lozano M; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain., Labarta Aizpún JI; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain., de Arriba Muñoz A; Unidad de Endocrinología Pediátrica, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Jazyk:	angličtina
Zdroj:	Anales de pediatria [An Pediatr (Engl Ed)] 2022 Mar; Vol. 96 (3), pp. 221-229. Date of Electronic Publication: 2022 Feb 28.
DOI:	10.1016/j.anpede.2021.04.008
Abstrakt:	Introduction: Short stature is the most frequent reason for consultation in Pediatric Endocrinology consultations and sometimes requires treatment with growth hormone. The aim of the study was to analyze the response to treatment based on its onset in pubertal or prepubertal stages and to analyze the possible benefit of an early onset. Patients and Methods: Longitudinal, retrospective and observational study in 139 patients treated for idiopathic growth hormone deficiency up to adult height. Main Variables Studied: (a) genetic background: maternal, paternal and genetic height; (b) perinatal history; (c) anthropometry during follow-up and at pubertal onset: weight, height, body mass index; (d) variables during follow-up and at pubertal onset: growth rate, bone age and growth prognosis. Final response variables: adult height, adult height with respect to target height, adult height with respect to initial growth prediction, adult height with respect to initial height at the start of treatment and adult height with respect to height at pubertal onset. Results: Total pubertal gain was 0.84 ± 0.6 SD. 61.9% of the patients started treatment with rhGH in prepuberty. The initiation of treatment in the prepubertal stage and a higher total pubertal gain are correlated with a better final height (P = 0.001 and r = 0.507, P = 0.00, respectively). Furthermore, a longer duration of treatment in pre-puberty is correlated with a better final response (r = 0.328, P = 0.00). Conclusions: The start of treatment in the prepubertal stage and its longer duration during this period are determining factors to achieve a good long-term response. Total pubertal gain was greater in patients who started treatment in the pubertal stage. (Copyright © 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu